Cited by 7,810Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentCancer Treatment and Pharmacology

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Open access

Conroy, Thierry, Desseigne, Françoise, Ychou, Marc, Bouché, Olivier, Guimbaud, Rosine, Bécouarn, Yves, Adenis, Antoine, Raoul, Jean-Luc, Gourgou-Bourgade, Sophie, de la Fouchardière, Christelle, Bennouna, Jaafar, Bachet, Jean-Baptiste, Khemissa-Akouz, Faiza, Péré-Vergé, Denis, Delbaldo, Catherine, Assenat, Eric, Chauffert, Bruno, Michel, Pierre, Montoto-Grillot, Christine, Ducreux, Michel·2011·New England Journal of Medicine

DOI 10.1056/nejmoa1011923

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as compared with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. METHODS: We randomly assigned 342 patients with an Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating a greater severity of illness) to receive FOLFIRINOX (oxaliplatin, 85 mg per square meter of body-surface area; irinotecan, 180 mg per square meter; leucovorin, 400 mg per square meter; and fluorouracil, 400 mg per square meter given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks) or gemcitabine at a dose of 1000 mg per square meter weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks. Six months of chemotherapy were recommended in both groups in patients who had a response. The primary end point was overall survival. RESULTS: The median overall survival was 11.1 months in the FOLFIRINOX group as compared with 6.8 months in the gemcitabine group (hazard ratio for death, 0.57; 95% confidence interval [CI], 0.45 to 0.73; P<0.001). Median progression-free survival was 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (hazard ratio for disease progression, 0.47; 95% CI, 0.37 to 0.59; P<0.001). The objective response rate was 31.6% in the FOLFIRINOX group versus 9.4% in the gemcitabine group (P<0.001). More adverse events were noted in the FOLFIRINOX group; 5.4% of patients in this group had febrile neutropenia. At 6 months, 31% of the patients in the FOLFIRINOX group had a definitive degradation of the quality of life versus 66% in the gemcitabine group (hazard ratio, 0.47; 95% CI, 0.30 to 0.70; P<0.001). CONCLUSIONS: As compared with gemcitabine, FOLFIRINOX was associated with a survival advantage and had increased toxicity. FOLFIRINOX is an option for the treatment of patients with metastatic pancreatic cancer and good performance status. (Funded by the French government and others; ClinicalTrials.gov number, NCT00112658.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa1011923

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cancer Statistics, 2010
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pancreatic Cancer
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016

Flagged first, then by citations

Show all 37 references

Research works printed but not linked: 3

Zeghari-Squalli N, 1999, Clin Cancer Res, 5, 1189
10.2307/2281868 · DOI · Paper page
Introduction and methods. In: Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985–1990. Oxford, England: Oxford University Press, 1990.

Sorted by citations

Items 901–1,000 of 1,032

Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?
Saad, E. D., Zalcberg, J. R., Péron, J., Coart, E., Burzykowski, T., & Buyse, M. E. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx179 · Cited by 70
Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study
Nishida, S., Ishikawa, T., Egawa, S., Koido, S., Yanagimoto, H., Ishii, J., Kanno, Y., Kokura, S., Yasuda, H., Oba, M. S., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0386 · Cited by 71
Nimotuzumab: beyond the EGFR signaling cascade inhibition
Mazorra, Z., Chao, L., Lavastida, A., Sanchez, B., Ramos, M., Iznaga, N., & Crombet, T. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.04.008 · Cited by 74
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial
Reni, M., Zanon, S. M., Peretti, U., Chiaravalli, M., Barone, D., Pircher, C. C., Balzano, G., Macchini, M., Romi, S., Gritti, E., et al. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30196-1 · Cited by 70
Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT)
Oar, A. J., Lee, M., Le, H. V., Hruby, G., Dalfsen, R., Pryor, D. I., Lee, D., Chu, J., Holloway, L. C., Briggs, A., et al. (2019) · Practical Radiation Oncology · doi:10.1016/j.prro.2019.07.018 · Cited by 70
Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
Bange, E. M., Doucette, A. G., Gabriel, P. E., Porterfield, F., Harrigan, J. J., Wang, R., Wojcieszynski, A. P., Boursi, B., Mooney, B., Reiss, K. A., et al. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00328 · Cited by 73
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
Sawada, M., Kasuga, A., Mie, T., Furukawa, T., Taniguchi, T., Fukuda, K., Yamada, Y., Takeda, T., Kanata, R., Matsuyama, M., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06945-8 · Cited by 69
Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma
Grant, R. C., Denroche, R. E., Jang, G. H., Nowak, K. M., Zhang, A. X. W., Borgida, A., Holter, S., Topham, J. T., Wilson, J. M., Dodd, A., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320730 · Cited by 70
CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma
Zhang, X., Detering, L., Sultan, D. H., Luehmann, H. P., Li, L., Heo, G. S., Zhang, X., Lou, L., Grierson, P. M., Greco, S., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c08185 · Cited by 69
Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?
Heredia-Soto, V., Rodrı́guez-Salas, N., & Feliú, J. (2021) · Cancers · doi:10.3390/cancers13081986 · Cited by 74
Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
Alva‐Ruiz, R., Yohanathan, L., Yonkus, J. A., Abdelrahman, A. M., Gregory, L. A., Halfdanarson, T. R., Mahipal, A., McWilliams, R. R., Ma, W. W., Hallemeier, C. L., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10991-2 · Cited by 69
Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept
Luo, W., Wen, T., & Qu, X. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02935-3 · Cited by 73
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)
Dragovich, T., Laheru, D. A., Dayyani, F., Bolejack, V., Smith, L., Seng, J., Burris, H. A., Rosen, P. J., Hidalgo, M. M., Ritch, P. S., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2499-4 · Cited by 69
The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer
Mohelníková-Duchoňová, B., Brynychová, V., Hlaváč, V., Kočík, M., Oliverius, M., Hlavsa, J., Honsová, E., Mazanec, J., Kala, Z., Melichar, B., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2246-2 · Cited by 69
Developments in metastatic pancreatic cancer: Is gemcitabine still the standard?
Ying, J. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i8.736 · Cited by 69
Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer
Chan, E. W., Arlinghaus, L. R., Cardin, D. B., Goff, L. W., Berlin, J. D., Parikh, A. A., Abramson, R. G., Yankeelov, T. E., Hiebert, S. W., Merchant, N. B., et al. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.04.013 · Cited by 71
A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative
Pishvaian, M. J., Bender, R. J., Matrisian, L. M., Rahib, L., Hendifar, A. E., Hoos, W. A., Mikhail, S., Chung, V. M., Picozzi, V. J., Heartwell, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13225 · Cited by 70
miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma
Tesfaye, A. A., Azmi, A. S., & Philip, P. A. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.10.005 · Cited by 72
Management of Locally Advanced Pancreatic Cancer
Reames, B. N., Blair, A. B., Krell, R. W., Groot, V. P., Gemenetzis, G., Padussis, J. C., Thayer, S. P., Falconi, M., Wolfgang, C. L., Weiss, M. J., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003568 · Cited by 70
Higher overall survival in metastatic pancreatic cancer: the impact of where and how treatment is delivered
Usón, P. L. S., França, M. S., Rodrigues, H. V., Macedo, A. L. D. V., Goldenberg, A., Smaletz, Ò., Pezzutti, D., Simon, S. D., & Gansl, R. C. (2015) · Einstein (São Paulo) · doi:10.1590/s1679-45082015ao3303 · Cited by 68
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer
Evans, T. R. J., Cutsem, E. V., Moore, M. J., Bazin, I. S., Rosemurgy, A. S., Bodoky, G., Deplanque, G., Harrison, M., Melichar, B., Pezet, D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw607 · Cited by 68
Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer
Weniger, M., Hank, T. P., Qadan, M., Ciprani, D., Michelakos, T. P., Niess, H., Heiliger, C., Ilmer, M., D’Haese, J. G., Ferrone, C. R., et al. (2020) · British journal of surgery · doi:10.1002/bjs.12003 · Cited by 71
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial
Janssen, Q. P., van Dam, J. L., van Bekkum, M. L., Bonsing, B. A., Bos, H., Bosscha, K. P., Bouwense, S. A. W., Brouwer-Hol, L., Bruynzeel, A. M. E., Busch, O. R., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00363-8 · Cited by 68
Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base
Rutter, C. E., Park, H. S.-M., Corso, C. D., Lester-Coll, N. H., Mancini, B. R., Yeboa, D. N., & Johung, K. L. (2015) · Cancer · doi:10.1002/cncr.29652 · Cited by 68
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines
Izetti, P., Hautefeuille, A. H., Abujamra, A. L., de Farias, C. B., Giacomazzi, J., Alemar, B., Lenz, G., Roesler, R., Schwartsmann, G., Osvaldt, A. B., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0090-9 · Cited by 70
Patient-reported outcomes as end points and outcome indicators in solid tumours
Secord, A. A., Coleman, R. L., Havrilesky, L. J., Abernethy, A. P., Samsa, G. P., & Cella, D. F. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.29 · Cited by 68
Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
Cui, Y., Brosnan‐Cashman, J. A., Blackford, A. L., Sur, S., Hruban, R. H., Kinzler, K. W., Vogelstein, B., Maitra, A., Diaz, L. A., Iacobuzio–Donahue, C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0827 · Cited by 68
Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma
Gurka, M. K., Kim, C. M., He, A. R., Charabaty, A., Haddad, N., Turocy, J. M., Johnson, L. B., Jackson, P. G., Weiner, L. M., Marshall, J. L., et al. (2014) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000118 · Cited by 68
Pain in pancreatic ductal adenocarcinoma: A multidisciplinary, International guideline for optimized management
Drewes, A. M., Campbell, C. M., Ceyhan, G. O., Delhaye, M., Garg, P. K., van Goor, H., Laquente, B., Morlion, B. J., Olesen, S. S., Singh, V. K., et al. (2018) · Pancreatology · doi:10.1016/j.pan.2018.04.008 · Cited by 68
Surgery for Recurrent Pancreatic Cancer: Is It Effective?
Moletta, L., Serafini, S., Valmasoni, M., Pierobon, E. S., Ponzoni, A., & Sperti, C. (2019) · Cancers · doi:10.3390/cancers11070991 · Cited by 68
Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands
Daamen, L. A., Groot, V. P., Besselink, M. G., Bosscha, K. P., Busch, O. R., Cirkel, G. A., van Dam, R. M., Festen, S., Koerkamp, B. G., Mohammad, N. H., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004093 · Cited by 68
Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer
Grunvald, M. W., Jacobson, R. A., Kuzel, T. M., Pappas, S. G., & Masood, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207651 · Cited by 70
Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer
Xu, J., Singh, A., & Amiji, M. M. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-75 · Cited by 68
Genetics and Biology of Pancreatic Ductal Adenocarcinoma
Dunne, R. F., & Hezel, A. F. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.04.003 · Cited by 68
Organoid model: A new hope for pancreatic cancer treatment?
Chen, H., Zhuo, Q., Zeng, Y., Xu, X., & Ji, S. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188466 · Cited by 69
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Zhou, X., An, J., Kurilov, R., Brors, B., Hu, K., Peccerella, T., Roessler, S. K., Pfütze, K., Schulz, A., Wolf, S., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00628-6 · Cited by 68
Long‐term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer
Arvold, N. D., Ryan, D. P., Niemierko, A., Blaszkowsky, L. S., Kwak, E. L., Wo, J. Y.-L., Allen, J. N., Clark, J. W., Wadlow, R. C., Zhu, A. X., et al. (2011) · Cancer · doi:10.1002/cncr.26633 · Cited by 67
Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy
Hamada, T., Nakai, Y., Yasunaga, H., Isayama, H., Matsui, H., Takahara, N., Sasaki, T., Takagi, K., Watanabe, T., Yagioka, H., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.131 · Cited by 70
Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells
Yen, W.-C., Fischer, M. M., Hynes, M. J., Wu, J., Kim, E. J.-H., Beviglia, L., Yeung, V. P., Song, X., Kapoun, A. M., Lewicki, J. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0736 · Cited by 67
SMAD4 Loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells
Chen, Y.-W., Hsiao, P., Weng, C., Kuo, K., Kuo, T., Wu, D., Hung, W., & Cheng, K. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-181 · Cited by 72
Advancements in the Management of Pancreatic Cancer: 2013
Saif, M. W. (2013) · PubMed · doi:10.6092/1590-8577/1481 · Cited by 67
Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells
Audenaerde, J. R. M. V., Waele, J. D., Marcq, E., Loenhout, J. V., Lion, E., den Bergh, J. M. J. V., Jesenofsky, R., Masamune, A., Roeyen, G., Pauwels, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18185 · Cited by 69
Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma
Meijer, L. L., Garajová, I., Caparello, C., Large, T. Y. S. L., Frampton, A. E., Vasile, E., Funel, N., Geert Kazemier, M., & Giovannetti, E. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000003084 · Cited by 69
FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden Experience
Moorcraft, S. Y., Khan, K. H., Peckitt, C., Watkins, D. J., Rao, S., Cunningham, D., & Chau, I. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.09.005 · Cited by 68
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities
Young, K., Hughes, D. J., Cunningham, D., & Starling, N. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918816281 · Cited by 66
Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles
Grapa, C. M., Mocan, T., Gonciar, D., Zdrehuş, C., Moșteanu, O., Pop, T., & MOCAN, L. C. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s226628 · Cited by 69
Recent advances in the treatment of pancreatic cancer
Roth, M. T., Cardin, D. B., & Berlin, J. D. (2020) · F1000Research · doi:10.12688/f1000research.21981.1 · Cited by 68
The unique immune microenvironment of liver metastases: Challenges and opportunities
Ciner, A., Jones, K. I., Muschel, R. J., & Brodt, P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.003 · Cited by 71
Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression
Cheng, C., Tan, H., Wang, N., Chen, L., Meng, Z., Chen, Z., & Feng, Y. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.467 · Cited by 70
Penetration Cascade of Size Switchable Nanosystem in Desmoplastic Stroma for Improved Pancreatic Cancer Therapy
Zhao, X., Yang, X., Wang, X., Zhao, X., Zhang, Y., Liu, S., Anderson, G. J., Kim, S.-J., Li, Y., & Nie, G. (2021) · ACS Nano · doi:10.1021/acsnano.0c08860 · Cited by 66
Improving outcomes of patients with pancreatic cancer
Dreyer, S. B., Beer, P. A., Hingorani, S. R., & Biankin, A. V. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01019-9 · Cited by 71
Management of Borderline Resectable Pancreatic Cancer
Katz, M. H. G., Crane, C. H., & Varadhachary, G. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2013.11.006 · Cited by 66
Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression
Palagani, V., Bozko, P. M., Khatib, M. E., Belahmer, H., Giese, N. A., Sipos, B., Malek, N. P., & Plentz, R. R. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt394 · Cited by 67
Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer
Shaib, W. L., Ip, A., Cardona, K., Alese, O. B., Maithel, S. K., Kooby, D. A., Landry, J. C., & El‐Rayes, B. F. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0316 · Cited by 66
Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review
Kristensen, A., Vagnildhaug, O. M., Grønberg, B. H., Kaasa, S., Laird, B. J. A., & Solheim, T. S. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.006 · Cited by 68
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease
ter Veer, E., van Rijssen, L. B., Besselink, M. G., Mali, R. M. A., Berlin, J. D., Boeck, S. H., Bonnetain, F., Chau, I., Conroy, T., Cutsem, E. V., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30098-6 · Cited by 66
Self-citation
Fucoidan-Manganese Dioxide Nanoparticles Potentiate Radiation Therapy by Co-Targeting Tumor Hypoxia and Angiogenesis
Shin, S.-W., Jung, W., Choi, C., Kim, S., Son, A.-R., Kim, H., Lee, N., & Park, H. C. (2018) · Marine Drugs · doi:10.3390/md16120510 · Cited by 66
Integrin α11 in pancreatic stellate cells regulates tumor stroma interaction in pancreatic cancer
Schnittert, J., Bansal, R., Mardhian, D. F., van Baarlen, J., Östman, A., & Prakash, J. (2019) · The FASEB Journal · doi:10.1096/fj.201802336r · Cited by 66
Probiotic‑derived ferrichrome inhibits the growth of refractory pancreatic cancer cells
Kita, A., Fujiya, M., Konishi, H., Tanaka, H., Kashima, S., Iwama, T., Ijiri, M., Murakami, Y., Takauji, S., Goto, T., et al. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5096 · Cited by 65
Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes
Varghese, A. M., Singh, I., Singh, R., Kunte, S., Chou, J. F., Capanu, M., Wong, W., Lowery, M. A., Stadler, Z. K., Salo‐Mullen, E. E., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab038 · Cited by 68
Immunotherapy in Pancreatic Adenocarcinoma: Beyond “Copy/Paste”
Hester, R., Mazur, P. K., & McAllister, F. M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0900 · Cited by 67
Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies
Bazeed, A. Y., Day, C. M., & Garg, S. (2022) · Cancers · doi:10.3390/cancers14174257 · Cited by 65
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study
Laethem, J. V., Borbath, I., Prenen, H., Geboes, K., Lambert, A., Mitry, E., Cassier, P. A., Blanc, J., Pilla, L., Feliú, J., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00263-8 · Cited by 67
Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine
Duong, H., Yi, Y. W., Kang, H. J., Hong, Y. B., TANG, W., Wang, A., Seong, Y., & Bae, I. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2229 · Cited by 65
PARP-1 Regulates Resistance of Pancreatic Cancer to TRAIL Therapy
Yuan, K., Sun, Y., Zhou, T., McDonald, J. M., & Chen, Y. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0516 · Cited by 67
Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer
Dimou, A., Syrigos, K. N., & Saif, M. W. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012446008 · Cited by 66
HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s
Li, L., Tang, W., Wu, X., Karnak, D. M., Meng, X., Thompson, R. H., Hao, X., Li, Y., Qiao, X. T., Lin, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0621 · Cited by 67
EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model
Singh, A., Xu, J., Mattheolabakis, G., & Amiji, M. M. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.11.010 · Cited by 65
Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer
Sideras, K., Biermann, K., Yap, K., Mancham, S., Boor, P. P. C., Hansen, B. E., Stoop, H., Peppelenbosch, M. P., van Eijck, C. H. J., Sleijfer, S., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30760 · Cited by 68
The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis
Gao, H.-L., Liu, L., Qi, Z.-H., Xu, H., Wang, W.-Q., Wu, C., Zhang, S.-R., Xu, J.-Z., Ni, Q.-X., & Yu, X. (2018) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2018.03.007 · Cited by 68
An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer
Ling, X., Wu, W., Fan, C., Xu, C., Liao, J., Rich, L. J., Huang, R.-Y., Repasky, E. A., Wang, X., & Li, F. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0899-8 · Cited by 65
Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review
Chiorean, E. G., Cheung, W. Y., Giordano, G., Kim, G., & Al-Batran, S. E. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919850367 · Cited by 66
Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency
Layer, P., Kashirskaya, N. Y., & Gubergrits, N. B. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i20.2430 · Cited by 66
A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome
Teriaca, M. A., Loi, M., Suker, M., Eskens, F. A. L. M., van Eijck, C. H. J., & Nuyttens, J. J. M. E. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.11.006 · Cited by 65
A bioengineered heterotypic stroma–cancer microenvironment model to study pancreatic ductal adenocarcinoma
Drifka, C. R., Eliceiri, K. W., Weber, S. M., & Kao, W. J. (2013) · Lab on a Chip · doi:10.1039/c3lc50487e · Cited by 64
Vaccine therapy for pancreatic cancer
Salman, B., Zhou, D., Jaffee, E. M., Edil, B. H., & Zheng, L. (2013) · OncoImmunology · doi:10.4161/onci.26662 · Cited by 64
Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma
Chen, R., Pan, S., Ottenhof, N. A., de Wilde, R. F., Wolfgang, C. L., Lane, Z., Post, J., Bronner, M. P., Willmann, J. K., Maitra, A., et al. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.20842 · Cited by 62
Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS ‐ PC study
Suzuki, N., Hazama, S., Iguchi, H., Uesugi, K., Tanaka, H., Hirakawa, K., Aruga, A., Hatori, T., Ishizaki, H., Umeda, Y., et al. (2016) · Cancer Science · doi:10.1111/cas.13113 · Cited by 65
Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy
Granata, V., Fusco, R., Setola, S. V., Piccirillo, M., Leongito, M., Palaia, R., Granata, F. M., Lastoria, S., Izzo, F., & Petrillo, A. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i26.4767 · Cited by 66
Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer
Khomiak, A., Brunner, M., Kordes, M., Lindblad, S., Miksch, R. C., Öhlund, D., & Regel, I. (2020) · Cancers · doi:10.3390/cancers12113234 · Cited by 70
From Machine Learning to Patient Outcomes: A Comprehensive Review of AI in Pancreatic Cancer
Tripathi, S., Tabari, A., Mansur, A., Dabbara, H., Bridge, C. P., & Daye, D. (2024) · Diagnostics · doi:10.3390/diagnostics14020174 · Cited by 70
Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation
Girelli, R., Prejanò, S., Cataldo, I., Corbo, V., Martini, L., Scarpa, A., & Claudio, B. (2015) · Radiology and Oncology · doi:10.1515/raon-2015-0013 · Cited by 64
Reappraisal of Peritoneal Washing Cytology in 984 Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Margin-Negative Resection
Satoi, S., Murakami, Y., Motoi, F., Uemura, K., Kawai, M., Kurata, M., Sho, M., Matsumoto, I., Yanagimoto, H., Yamamoto, T., et al. (2014) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-014-2637-7 · Cited by 64
MicroRNA-216a inhibits pancreatic cancer by directly targeting Janus kinase 2
Wang, S., CHEN, X., & Tang, M. (2014) · Oncology Reports · doi:10.3892/or.2014.3478 · Cited by 66
Clinical Outcomes of Chemotherapy for Diabetic and Nondiabetic Patients With Pancreatic Cancer
Nakai, Y., Isayama, H., Sasaki, T., Mizuno, S., Sasahira, N., Kogure, H., Kawakubo, K., Yamamoto, N., Hirano, K., Ijichi, H., et al. (2012) · Pancreas · doi:10.1097/mpa.0b013e31825de678 · Cited by 64
Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer
Shindo, Y., Hazama, S., Maeda, Y., Matsui, H., Iida, M., Suzuki, N., Yoshimura, K., Ueno, T., Yoshino, S., Sakai, K., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-175 · Cited by 64
Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial
Scheithauer, W., Ramanathan, R. K., Moore, M. J., Macarulla, T. M., Goldstein, D., Hammel, P. R., Kunzmann, V., Liu, H., McGovern, D. M. T., Romano, A., et al. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.01.03 · Cited by 67
GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer
Pelosof, L. C., Yerram, S. R., Armstrong, T. D., Chu, N. J., Danilova, L., Yanagisawa, B., Hidalgo, M. M., Azad, N. S., & Herman, J. G. (2016) · Epigenetics · doi:10.1080/15592294.2016.1265711 · Cited by 64
Multifaceted peptide assisted one-pot synthesis of gold nanoparticles for plectin-1 targeted gemcitabine delivery in pancreatic cancer
Pal, K., Al-suraih, F., González-Rodríguez, R., Dutta, S. K., Wang, E., Kwak, H. S., Caulfield, T. R., Coffer, J. L., & Bhattacharya, S. (2017) · Nanoscale · doi:10.1039/c7nr03172f · Cited by 64
Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness
Rademaker, G., Hennequière, V., Brohée, L., Nokin, M., Lovinfosse, P., Durieux, F., Gofflot, S., Bellier, J., Costanza, B., Herfs, M. F., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0287-z · Cited by 65
IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Mirlekar, B., Michaud, D. E., Searcy, R., Greene, K., & Pylayeva‐Gupta, Y. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0710 · Cited by 66
A Subset of New Platinum Antitumor Agents Kills Cells by a Multimodal Mechanism of Action Also Involving Changes in the Organization of the Microtubule Cytoskeleton
Kostrhunová, H., Zajac, J., Novohradský, V., Kašpárková, J., Malina, J., Aldrich-Wright, J. R., Petruzzella, E., Sirota, R., Gibson, D., & Brabec, V. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00489 · Cited by 64
Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages
Chen, Q., Wang, J., Zhang, Q., Zhang, J., Lou, Y., Yang, J., Chen, Y., Wei, T., Zhang, J., Fu, Q., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0595-2 · Cited by 64
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models
Dunlop, C. R., Wallez, Y., Johnson, T. I., Fernández, S. B. D. Q., Durant, S. T., Cadogan, E. B., Lau, A., Richards, F. M., & Jodrell, D. I. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-1016-2 · Cited by 64
Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
Abraham, J. P., Magee, D., Cremolini, C., Antoniotti, C., Halbert, D. D., Xiu, J., Stafford, P., Berry, D. A., Oberley, M. J., Shields, A. F., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3286 · Cited by 67
Myeloid Growth Factors
Crawford, J., Armitage, J. O., Balducci, L., Becker, P. S., Blayney, D. W., Cataland, S. R., Heaney, M. L., Hudock, S., Kloth, D. D., Kuter, D. J., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0148 · Cited by 64
Overall Survival: Patient Outcome, Therapeutic Objective, Clinical Trial End Point, or Public Health Measure?
Saad, E. D., & Buyse, M. E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6359 · Cited by 64
Neoplasms of the Exocrine Pancreas
Wolff, R. A., Crane, C. H., Li, D., Evans, D. B., Maitra, A., & Tsai, S. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm094 · Cited by 64
A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer
Shinoto, M., Terashima, K., Suefuji, H., Matsunobu, A., Toyama, S., Fukunishi, K., & Shioyama, Y. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.08.026 · Cited by 63
Pancreatic Cancer Heterogeneity Can Be Explained Beyond the Genome
Juiz, N. A., Iovanna, J., & Dusetti, N. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00246 · Cited by 63

Authors: Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., Bennouna, J., Bachet, J.-B., Khemissa-Akouz, F., Péré-Vergé, D., Delbaldo, C., Assenat, E., Chauffert, B., Michel, P., Montoto-Grillot, C., & Ducreux, M.
Affiliations: Centre Léon Bérard (FR)
Centre Hospitalier Universitaire de Reims (FR)
Institut Claudius Regaud (FR)
Institut Bergonié (FR)
Centre Oscar Lambret (FR)
Centre Eugène Marquis (FR)
Hôpital Ambroise-Paré (FR)
Centre Hospitalier de Perpignan (FR)
Hôpital de la Croix-Rousse (FR)
Centre Hospitalier Universitaire Henri-Mondor (FR)
Centre Georges François Leclerc (FR)
Université de Rouen Normandie (FR)
UniCancer Group (FR)
Institut Gustave Roussy (FR)
ORCID: Conroy, Thierry
Ychou, Marc
Bouché, Olivier
Guimbaud, Rosine
Adenis, Antoine
Raoul, Jean-Luc
Bennouna, Jaafar
Bachet, Jean-Baptiste
Khemissa-Akouz, Faiza
Michel, Pierre
Montoto-Grillot, Christine
Ducreux, Michel
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2011-05-12
Volume: 364
Issue: 19
Pages: 1817-1825
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1011923
OpenAlex: W2151253787
Cited by: 7,810
References: 37
Citations by year: 2026: 425 · 2025: 521 · 2024: 560 · 2023: 604 · 2022: 622 · 2021: 785 · 2020: 692 · 2019: 563 · 2018: 577 · 2017: 558 · 2016: 454 · 2015: 473 · 2014: 388 · 2013: 282 · 2012: 222
FWCI: 150.63
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords: FOLFIRINOX, gemcitabine, metastatic pancreatic cancer, first-line chemotherapy, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, overall survival, progression-free survival, objective response rate, febrile neutropenia, quality of life, adverse events, combination chemotherapy, randomized trial comparison
MeSH terms: Irinotecan, Oxaliplatin, Gemcitabine, Adenocarcinoma, Adult, Aged, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Deoxycytidine, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Pancreatic Neoplasms, Quality of Life, Severity of Illness Index, Proportional Hazards Models, Survival Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks